A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma
Conditions
Other Urinary
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Ages18 years and older
- GenderBoth
- Trial withMirati Therapeutics
- Start Date02/23/2020
- End Date01/30/2021
For more information about this study, contact:
Matthew Piscatelli
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- David Witt, MD
- Hari Deshpande, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jaykumar Thumar, MBBS, MD
- Joseph Kim, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Lynn Cochran
- Michael Cohenuram, MD
- Michael Hurwitz, PhD, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Last Updated07/23/2020
- Study HIC#2000024557